Elixir Medical

Elixir Medical is an early-stage, private medical device company targeting the massive and underserved cardiovascular disease market. The company is developing transformative platforms for percutaneous coronary intervention (PCI) and peripheral interventions, aiming to address significant unmet needs such as high rates of adverse events and disease recurrence. While still in a pre-revenue, pre-clinical/development stage, Elixir positions itself as a disruptor seeking to reshape vascular medicine for decades to come by tackling problems where others have given up.

Undisclosed platform technology focused on transformative solutions for coronary and peripheral vascular interventions, aiming to address limitations of current standard-of-care like high rates of adverse events post-procedure.

Elixir will compete against giant, well-funded medical device companies like Abbott, Medtronic, Boston Scientific, and Philips in the coronary and peripheral stent/balloon markets. It may also face competition from other startups developing next-generation bioresorbable scaffolds, drug-coated balloons, and combination devices.